Drug
Barusiban clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2003 (1)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses barusiban is read from its arms, and is right about nine times in ten.
Testing it · 4
- Effect of Oxytocin Antagonist on Reduction of Uterine ContractionsCompletedPhase 2Ferring PharmaceuticalsNCT01043120Written as Barusiban
- Effect of Oxytocin and Vasopressin Antagonists on Uterine ContractionsCompletedPhase 2Ferring PharmaceuticalsNCT00587327Written as Barusiban
- Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine ContractionsCompletedPhase 2Ferring PharmaceuticalsNCT01723982Written as Barusiban (FE 200440)
- A Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 and Placebo on Stopping Preterm LaborCompletedPhase 2Ferring PharmaceuticalsNCT00209326Written as FE200440
Codes
What other systems call barusiban · ClinicalTrials.gg INT005036
- MeSH (NLM) C517339barusibanOne source NLM
- UNII (FDA) UX33I93GLSBARUSIBANConfirmed FDA, NLM, Wikidata
- Wikidata Q19596024barusibanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90866BarusibanOne source FDA
- DrugBank DB12292One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C517339 | barusiban | One source NLM |
| UNII (FDA) | UX33I93GLS | BARUSIBAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q19596024 | barusiban | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90866 | Barusiban | One source FDA |
| DrugBank | DB12292 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.